Interim Editor of In Vivo
Jo Shorthouse is the Interim Editor of In Vivo. She has contributed to various Pharma Intelligence publications, starting with Scrip in 2008. She has previously edited Scrip Good Clinical Practice, Scrip Clinical Research and the Scrip 100, been a managing editor on Pharma Intelligence’s Commercial team, and most recently turned her hand to freelance health care journalism and editorial consultancy. Jo has a wide-ranging knowledge of many aspects of the pharmaceutical industry which allows her to bring insights to the Pharma Intelligence and In Vivo teams.
Latest From Jo Shorthouse
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.
Deana Mohr, Muvon Therapeutics’ co-founder and chief executive, and one of In Vivo’s 2022 Rising Leaders, aspires to push the organization to the next level by scaling up the company and developing its therapies into marketable products.
The maturation of digital offerings, coupled with commercially and clinically successful partnerships, has enabled huge investments in the digital health industry.
Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.
Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.
Two years into her tenancy as CEO, Bahija Jallal is on the cusp of taking UK biotech Immunocore from a research and development organization to a company with a burgeoning pipeline and a marketed therapy. She talks to In Vivo about validating the platform, an IPO and creating a commercial footprint.